Kornimate/medical-research-clean huggingface dataset:
response of urticaria to stress intervention

Conditions: Chronic Urticaria

Summary: several studies have shown a relationship between psychological stress and chronic urticaria (hives). the primary objective of this study is to evaluate the effect psychological stress intervention has on chronic urticaria.

as many patients with chronic urticaria display heightened levels of stress before and/or after the onset of the urticaria, the purpose of this study is to evaluate the effect of psychological stress intervention on chronic urticaria. intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques. control group participants will meet with a psychiatry resident once a week for six consecutive weeks for general supportive therapy, which will not provide psychological stress intervention. all participants will complete a packet of psychological and dermatological questionnaires before the first session with the psychiatry resident and one week after the final session. all participants will record daily 1) their urticaria symptoms and 2) the type and number of antihistamines taken. blood and saliva samples will be collected before the first session and one week after completion of the final session to compare the levels of stress hormones and cytokines in order to evaluate an effect on immune dysregulation.

Eligibility criteria:
inclusion criteria: * males and females age 18-64 years who are inadequately controlled on h1 and/or h2-blocker therapy for chronic urticaria * the urticaria activity score must have a score of at least 2 (one point from each of the two categories: number of hives and severity of pruritus). exclusion criteria: * urticaria secondary to vasculitis * use of prednisone, hydroxychloroquine, cyclosporine, or a tricyclic antidepressant (except doxepin) within the 30 days prior to enrollment * a history of anaphylaxis * non-controlled or debilitating chronic diseases (poorly controlled diabetes or congestive heart failure) * an immune system disorder * deranged stress hormone level (for example, cushing's disease) * ongoing omalizumab therapy * nocturnal employment (which would effect study measures, such as cortisol levels).

Keywords: urticaria hives stress immune dysregulation
splenda: effects on blood glucose concentration, appetite scores and subsequent energy intake

Conditions: Appetitive Behavior; Glucose Metabolism Disorders

Summary: this study investigates the effects of splenda, an artificial sweetener powder containing sucralose, on post-prandial blood glucose levels, appetite scores and subsequent energy intake.

participants are randomly assigned to receive either the placebo drink (4.5g maltodextrin dissolved in 250ml water) or the splenda drink (4.5g splenda dissolved in 250ml water) taken alongside a high calorie breakfast. blood glucose measurements will be obtained through finger-pricking and appetite will be measured using self-reported visual analogue scores rating hunger, desire to eat, fullness and alertness for up to 3 hours after breakfast. energy intake will be measured using a 24 hour food diary.

Eligibility criteria:
inclusion criteria: * healthy male and female adults (18-64 years) exclusion criteria: -

Keywords: blood glucose appetite energy intake
effect of aerobic exercise with blood flow restriction on post-exercise hypotension in young adults: the role of histamine receptors

Conditions: Prehypertension (elevated Blood Pressure) or Hypertension

Summary: it was hypothesized that aerobic exercise with blood flow restriction (bfr) induced post exercise hypotension (peh), and the reduction in blood pressure (bp) was due to peripheral vasodilation via the histamine receptors. ten male participants participated in this study. the participants were randomly assigned to walk for 10 minutes at 6.4 k/m, 0% grade with or without bfr after taking histamine receptor blockade. following exercise, bp was measured at 10 min interval for 60 minutes. heart rate (hr), stroke volume (sv), cardiac output (co), mean arterial pressure (map), and total peripheral resistance (tpr) were evaluated.


Eligibility criteria:
inclusion criteria: * good health, * nonsmokers * those not taking medications that could affect cardiovascular function exclusion criteria: * hypertension * muscular skeletal disorder
measurement of the efficacy of morphine in the early management of dyspnea in covid-19 positive patients

Conditions: Patients Hospitalized in the Hospices Civils of Lyon; COVID-19 Disease; Moderate to Severe Dyspnea; Without Resuscitation Objective Management

Summary: morphine is used in the treatment of dyspnea and polypnea with a proven benefit on the improvement of these symptoms, both etiologically and symptomatically. this medication is used in particular in palliative care for this type of symptom. the sars cov2 viral pneumonia table can lead to respiratory distress. in patients with moderate to severe impairment without goal of resuscitation (level of care 3 and 4), the introduction of morphine may sometimes be necessary to relieve respiratory symptoms. these also lead to major exhaustion which can worsen the clinical picture. however, the prescription of morphine is not systematic in front of a respiratory distress table. the investigators hypothesized that early treatment with morphine lead to a better management of dyspnea, quality of live and survival in covid-19 positive participants patients when there is not resuscitation objective management (level of care 3 and 4). the objective is to measure the efficacy of morphine in the early management of dyspnea, quality of life and survival in covid-19 positive participants patients treated in the hospices civils of lyon during covid-19 pandemic.


Eligibility criteria:
inclusion criteria: * age over 18 years. * having had a covid-19 respiratory disease confirmed by pcr or tdm or anamnestic criterion for patients living in communities for the elderly (respiratory symptomatology suggestive and at least 3 cases confirmed in the living environment). * having had respiratory severity criteria: respiratory distress syndrome including fr\> 25 / min and oxygen-demand\> 4 l / min to maintain a spo2\> 90% at inclusion. * having had a defined level of care after collegial discussion notified in the file rejecting the external cardiac massage and admission to the intensive care unit (level 3 and 4 on the protocols of the hospices civils de lyon). * collection of non-opposition exclusion criteria: -

Keywords: covid-19 disease level of care 3 and 4 morphinic treatment dyspnea
cilnidipine effect on high blood pressure and cerebral perfusion in ischemic stroke patients with hypertension

Conditions: Hypertension; Stroke

Summary: the purpose of this study is to compare the effect of cilnidipine (a calcium channel blocker) and losartan (an angiotensin ii receptor blocker) on cerebral blood flow (cbf) and blood pressure in hypertensive patients with a previous ischemic stroke.

design: multi-center, randomized, double-blind, active control, titrated dose, non-inferiority trial population studied: we will prospectively recruit 250 hypertensive patients who had ischemic stroke 2 or more weeks previously and were admitted at 7 centers in the seoul metropolitan area in south korea. interventions: after a 2-week washout period, all patients will undergo baseline 99mtc-hmpao single photon emission computed tomography (spect), blood pressure evaluation, nihss examination, and laboratory test prior to treatment. the patients will be randomized to receive either cilnidipine 10-20mg or losartan 50-100mg once daily for 4 weeks with a target systolic blood pressure of \< 140mmhg and diastolic blood pressure of \< 90mmhg. after 4-week treatment, all patients will receive follow-up spect and blood pressure evaluation. for the quantitative cbf analysis, spect will be performed with a single machine in one center. outcome measures: primary outcome measure is the percentile change of global cbf on spect between pre- and post-treatments. secondary outcome measures include the percentile change of regional cbf, the proportion of patients less than 8.6% decrease of global cbf, and the change of nihss score.

Eligibility criteria:
inclusion criteria: * ischemic stroke patients with hypertension exclusion criteria: * cardioembolic stroke patients * severe hypertensive patients * secondary hypertensive patients

Keywords: cherish ischemic stroke
the efficacy and safety of electronic cigarettes: a 5-year follow-up study

Conditions: Cardiovascular Diseases; Chronic Obstructive Pulmonary Diseases; Cancer of the Lung; Cancer of the Bladder; Cancer of the Stomach

Summary: the main aim of this multicentric 5-year follow-up study is to evaluate for the first time the long-term efficacy and safety (in terms of smoking-related serious diseases requiring hospitalization) of e-cigarette smoking, comparing its health effects with those of traditional cigarette smoking and mixed electronic and traditional cigarette smoking. the study will also permit to evaluate, over a 5-year follow-up, the self-reported quality of life, and the reported adverse events according to current and past smoking habit. finally, the study will also explore the long-term adherence to e-cigarette smoking and its efficacy of e-cigarettes in reducing and/or quitting traditional cigarette smoking.


Eligibility criteria:
inclusion criteria: * resident into the abruzzo and lazio region * aged between 30 and 75 years; * smoker of e-cigarettes (inhaling at least 50 puffs per week) containing nicotine since six or more months (e-cigarettes only group); * smoker of at least one traditional cigarette per day since six or more months (traditional cigarettes only group); * smoker of both electronic and traditional cigarettes (at least one per day) since six or more months (mixed group). exclusion criteria: * illicit drug use, * breastfeeding or pregnancy, * major depression or other psychiatric conditions, * severe allergies, * active antihypertensive medication, * angina pectoris, * past episodes of major cardiovascular diseases (myocardial infarction, stroke/tia, congestive heart failure, copd, cancer of the lung, esophagus, larynx, oral cavity, bladder, pancreas, kidney, stomach, cervix, and myeloid leukemia.

Keywords: e-cigarette smoking cigarette smoking cardiovascular disease hospitalization chronic obstructive pulmonary diseases observational study efficacy safety
biomarkers in prehospital rule-out of intracranial lesions in tbi patients

Conditions: Traumatic Brain Injury

Summary: the pretbi i study will investigate whether prehospital blood samples drawn already in the ambulance can rule-out intracranial lesions in patients suffering head trauma. the study aims to improve triage and treatment of patients suffering mild head trauma, who are considered low-risk patients. these patients do not always benefit from hospitalization, but are nevertheless admitted on precaution, as clinical assesment can be difficult. hypotheses: 1. a prehospital measurement of serum s100b ≤ 0,10 microgram/l in mild tbi patients rules out traumatic intracranial lesion with a sensitivity \>97%. 2. a prehospital measurement of serum gfap (glial acidic fibrillary protein) in mild tbi patients rules out traumatic intracranial lesion with sensitivity \>97% and results in lower false positive rate than s100b. 3. prehospital measurements of both gfap and s100b results in lower false positive rates than in-hospital measurements.


Eligibility criteria:
inclusion criteria: * patients presenting with glasgow coma score (gcs) ≥13-15 and a loss of consciousness for less than 30 min and/or alteration of mental state (being dazed, confused or disorientated) and/or loss of memory for events immediately before and/or after the trauma. the emergency medical service staff will be guided through the inclusion and consent procedures by a simple tablet algorithm. exclusion criteria: * patients \ 6 hours elapsed after trauma, unknown time of trauma, multi trauma, known dementia, chronic psychosis or active central nervous system pathology.
pioglitazone and sglt2 inhibitors vs. dpp4 inhibitors in patients with stroke

Conditions: Diabetes Mellitus; Stroke

Summary: introduction: an optimal combination of antidiabetic drugs for diabetic patients with ischemic stroke is not well-established. the objective of this randomized trial is to evaluate whether combination of pioglitazone and a sodium glucose cotransporter 2 (sglt-2) inhibitor, compared with a dipeptidyl peptidase-4 (dpp-4) inhibitor, reduces recurrent stroke in diabetic patients with recent ischemic stroke. methods and analysis: the trial is a randomized, parallel-group study conducted at 7 hospitals in taiwan. inclusion criteria are adult patients with a history of ischemic stroke within 3 months, diabetes mellitus with hba1c \> 7%, taking metformin currently or previously, and estimated glomerular filtration rate ≥ 45 ml/min/1.73 m2. eligible patients who sign the informed consent forms will be randomly assigned in a 1:1 ratio to receive either combination of pioglitazone and an sglt2 inhibitor (empagliflozin or dapagliflozin or canagliflozin) vs. a dpp4 inhibitor. primary outcome is change in hba1c between 6 months and baseline in active vs comparator groups. additional biomarker outcomes are change in hs-crp insulin resistance, b type natriuretic peptide, and urine albumin creatinine ratio between 6 months and baseline. ethics and dissemination study protocol was approved by the institutional review board of chang gung memorial hospital, chiayi branch, taiwan (201702353a3, 201802340a3 and 201902176a3). all participants will be required to sign and date an informed consent form. study findings will be disseminated via a peer-reviewed journal.


Eligibility criteria:
inclusion criteria: 1. ischemic stroke within 3 months of randomization 2. type 2 diabetes mellitus and hba1c \> 7.0% and under metformin therapy currently or previously 3. estimated glomerular filtration rate (egfr) ≥ 45 ml/min/1.73 m2 4. age ≥ 20 y at study entry 5. ability and willingness to provide informed consent exclusion criteria: 1. history of congestive heart failure (nyha class 1-4) 2. history of bladder cancer 3. history of repeated (\> 2 episodes) urinary tract infection or genital tract infection 4. irreversible medical conditions with predicted survival \< 1 years 5. current use of an insulin 6. current use of a glucagon-like peptide-1 receptor agonist 7. current use of pioglitazone or an sglt-2 inhibitor

Keywords: stroke diabetes mellitus sodium-glucose transport protein 2 inhibitor pioglitazone
oncology research information exchange network in improving genetic screening rate in patients with cancer

Conditions: Malignant Neoplasm

Summary: this research trial studies how well oncology research information exchange network (orien) works in improving genetic screening rate in patients with cancer. implementation of progeny genetic pedigree and family history questionnaire software across all orien member institutions may add value and utility for recognizing and caring for patients with an inherited susceptibility to cancer.

primary objectives: i. measure the change in uptake of cancer genetic referrals and genetic testing in the orien system of cancer centers implementing the progeny family history questionnaire (fhq). secondary objectives: i. follow and estimate utilization of preventive health behaviors among progeny fhq users across all institutions. ii. compare utilization of preventive health behavior between progeny fhq risk identification and genetic testing. outline: patients take progeny genetic pedigree and family history questionnaire. results are reviewed by the site specific research coordinator and/or genetic counselor to assess whether a patient fulfills criteria for referral to the site specific cancer genetics clinic for further evaluation. after completion of study, patients are followed up at 6 months after disclosure of genetic testing results.

Eligibility criteria:
inclusion criteria: * limited to those patients who are consented to the total cancer care protocol (tccp) protocol * able to understand and sign the tccp informed consent, california subject?s bill of rights, health insurance portability and accountability act (hipaa), and research authorization form directly or through an authorized representative; the informed consent, subject?s bill of rights, hipaa, and research authorization will be available in both english and spanish languages exclusion criteria: * individuals who are not registered as patients for outpatient or inpatient care to the tccp protocol * individuals who are unable to understand or sign the tccp informed consent, subject?s bill of rights, hipaa, and research authorization in either english or spanish
clinical and economic impact of duodopa: long-term effectiveness study in advanced parkinson's disease patients

Conditions: Parkinson's Disease

Summary: the goal of this multicentric prospective randomized controlled clinical and economic study is to investigate the effectiveness and cost-utility of long-term continuous intraduodenal infusion of levodopa ( duodopa), compared to best medical treatment, on advanced and severe form of parkinson's disease.


Eligibility criteria:
inclusion criteria : * age\> 18 years and ≤ 80 years * akineto-hypertonic and/or tremor forms of parkinson's disease as defined by the criteria of the french national consensus conference for parkinson's disease (march 2000) * absence of parkinsonism other than a parkinson's disease, including absence of one or more of the following signs: autonomic syndrome, hallucinations, pyramidal signs, early postural instability, early cognitive impairment (including apraxia or severe frontal lobe syndrome) (consensus conference, march 2000) * severe and advanced forms of parkinson's disease with sensitivity to l-dopa (≥ 40%) * no contraindication to duodopa®: hypersensitivity to levodopa and carbidopa, or any of the excipients, angle-closure glaucoma, kidney and liver failures, severe heart failure, severe cardiac arrhythmia, acute stroke, pheochromocytoma, hyperthyroidism, cushing syndrome, association with non-selective maois and selective maois-a (stop at least 2 weeks before initiation of duodopa®) * fluctuations in motor performance (with off time ≥ 2 hours per day) and/or dyskinesia induced by l-dopa altering significantly the activities of daily life in spite of an optimized treatment * hoehn and yahr score \< 4 in best on * ability to complete a diary of self-evaluation (with the help of another person if necessary) * mmse ≥ 24/30 * no evolutive psychosis or history of severe psychosis requiring hospitalization * no digestive disease or ent evolutionary * no concomitant treatment by continuous infusion of apomorphine * no concomitant treatment by deep brain stimulation * no serious somatic disease likely to interfere with a good participation to the study, contraindication for gastrostomy * menopause proven or woman of childbearing potential with an effective contraception (hormonal / mechanical: oral, injectable, transdermal, implantable, intrauterine device, or surgery: ligation of the fallopian tubes, hysterectomy, total ovariectomy) exclusion criteria: * age \ 80 years * no signature of the informed consent form * patient with no social insurance or who cannot benefit it through a third person in accordance with the french law on biomedical research * population under enhanced protection (i.e minors), pregnant women, breast-feeding women, persons deprived of their liberty by a judicial or administrative decision, people in health and social service, adults under legal protection, and finally patients in emergency situations.

Keywords: advanced severe form
conbercept for polypoidal choroidal vasculopathy（start study）

Conditions: Polypoidal Choroidal Vasculopathy; Conbercept

Summary: 1. to evaluate the effectiveness of conbercept for pcv patients. 2. to describe the characteristics of pcv. 3. to describe the adverse events (ae) of conbercept in the treatment of pcv. 4. todescirbe the real situation and prognosis of pcv patients in our country.

1. to observe the visual changes in pcv patients receiving conbercept treatment, so as to evaluate the effectiveness of the treatment. changes of oct, icga, quality of life and visual function would be observed and evaluated. 2. to observe and describe the characteristics of pcv. 3. to observe and describe the incidence of adverse events (ae) and serious adverse events (sae) of conbercept in the treatment of pcv, so as to evaluate the safety of this treatment. 4. to observe and descirbe the real situation and prognosis of pcv patients in our country.

Eligibility criteria:
inclusion criteria: * according to the current diagnostic criteria, diagnosed as pcv patients * conbercept is used for treatment, and the recommended treatment scheme is 3+prn * local and systemic anti-vegf therapy was not used for at least three months before enrollment * the patient volunteers to take part in this observational study, and signs the informed consent * the patient can follow-up regularly (at least 4 times of follow-up in one year) exclusion criteria: * the patient has serious systemic disease, and the current clinical treatment is contraindicated * local or systemic anti-vegf therapy was used for less than three months before enrollment * existence of diseases unsuitable to accept intravitreal conbercept, including uncontrolled hypertension and diabetes, aids, malignant tumors, active hepatitis, severe renal failure, severe mental, nerve, cardiovascular, respiratory and immune diseases * during six months before screening, there were cardiovascular events such as stroke, transient ischemic attack, myocardial infarction or acute congestive heart failure * ocular contraindications, including active intraocular inflammation, infectious endophthalmitis, corneal ulcer, scleritis, uncontrolled glaucoma and so on * patients who could not follow up regularly * patients who refuse to sign the informed consent * others

Keywords: registration study polypoidal choroidal vasculopathy conbercept
bronchoscopic intrabullous autologous blood instillation (biabi) for emphysema

Conditions: Bullous Emphysema

Summary: patients with large bullae (large empty air sacs in the lung) may benefit from bullectomy (surgery to resect these bullae), however this is a major surgery with significant potential morbidity and long hospital stays. many patients are not well enough to have this surgery, or may not wish to have it. a less invasive means of attempting to shrink the size of the bullae is to directly inject the patients' own blood into the bullae (we believe that this can lead to an inflammatory reaction leading to gradual scarring and volume loss). this can be performed bronchoscopically in a 20-30 minute procedure using conscious sedation (avoiding general anaesthesia). the aim of this study is to assess the effects on lung function, quality of life measures, functional measures and ct measured lung volumes of bronchoscopic intrabullous blood instillation in patients with bullous emphysema.


Eligibility criteria:
inclusion criteria: * age \> 35 years * large bulla on ct scan where bullectomy is contraindicated or is actively avoided. * hyperinflation - tlc ≥100% predicted, rv ≥150% predicted * exertional breathlessness (mmrc \>0) * optimum copd treatment for at least 6 weeks * no copd exacerbation for at least 6 weeks * fewer than 3 admissions for infective exacerbations in the preceding 12 months * written informed consent exclusion criteria: * inability to obtain informed consent * co-morbidities that would render bronchoscopy or sedation unsafe. * anaemia or other reasons precluding venesection. * clinically significant bronchiectasis * arrhythmia or cardiovascular disease that poses a risk during procedure * lung nodule requiring further investigation or treatment * subject taking clopidogrel, warfarin, or other anticoagulants and unable to abstain for 5 days pre-procedure

Keywords: emphysema chronic obstructive pulmonary disease copd bulla interventional bronchoscopy lung volume reduction